What is Oramed Pharmaceuticals Inc.'s (ORMP) StockRank?

MoatMap's StockRank for Oramed Pharmaceuticals Inc. (ORMP) is 80/100, with a Strong Buy signal. This is a composite score combining Quality (64), Value (46), and Momentum (66) factor ranks across MoatMap's universe of 25,000+ stocks.

Does Oramed Pharmaceuticals Inc. have an economic moat?

Oramed Pharmaceuticals Inc. (ORMP) has a Quality factor score of 64/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage: the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Oramed Pharmaceuticals Inc. a buy, hold, or sell?

MoatMap's current signal for Oramed Pharmaceuticals Inc. (ORMP) is Strong Buy, based on a StockRank of 80/100. Signals are derived mechanically from the StockRank composite and should be one input among many; combine with your own thesis on management, competitive position, and valuation.

What sector is Oramed Pharmaceuticals Inc. in?

Oramed Pharmaceuticals Inc. (ORMP) operates in the Healthcare sector, specifically the Biotechnology industry (United States).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

ORMP

Strong BuyPremium Grower

Oramed Pharmaceuticals Inc. · Healthcare · United States · $209M · Avg Vol: $1M/d

StockRank

Get insider-trade alerts

P/E (TTM)

1.2x

ROE

74.2%

D/E

0.0x

Dividend %

5.0%

COMPANY DESCRIPTION

Oramed Pharmaceuticals Inc. is a clinical-stage pharmaceutical company pioneering oral drug delivery systems, notably an oral insulin capsule for diabetes. Its proprietary POD™ technology aims to transform injectable treatments into convenient oral alternatives, offering significant potential market disruption. Oramed is a biotech player developing innovative solutions for chronic diseases.

FINANCIAL SUMMARY (USD)

Year	2021	2022	2023	2024	2025	CAGR	TTM	2026E	Fwd CAGR
Revenue	2.7M	2.7M	1.3M	0	2.0M	-7.3%	—	—	—
EPS	-0.78	-0.94	0.14	-0.48	1.53	230.6%	4.13	4.47	192.2%
Shares	35.3M	39.6M	40.3M	39.9M	39.3M	+11.3%	41.6M	—	—
Debt	0.5M	0.9M	51.6M	0.4M	0.8M	11.5%	0.7M	—	—
Equity	115.8M	151.8M	163.8M	146.3M	199.7M	14.6%	—	—	—
Op CF	-21.2M	-27.9M	-10.3M	-8.4M	-9.1M	—	-5.2M	—	—
Inv CF	-23.8M	30.2M	-73.0M	105.8M	5.4M	—	—	—	—
Fin CF	102.9M	10.8M	52.0M	-52.0M	-4.7M	—	—	—	—

Loading 1Y...

PRICE (1Y)+15.5%

SMA 50SMA 200

$4.76

RSI (14)

49.1

52W High

$5.47

From 52W High

0.9%

SCORE BREAKDOWN

Quality

ROIC

37.2%97.6

ROE

74.2%98.7

GP/Assets

0.0%9.6

Op. Margin

0.0%38.1

FCF/Assets

n/mN/A

Piotroski

438.9

Int. Cover

50.0x89.2

D/E Ratio

0.00x91.9

Current Ratio

4.98x72.1

Value

P/E (TTM)

1.2x25.0

EV/EBITDA

-10.8x25.0

P/FCF

n/mN/A

P/B

0.7x93.9

P/S

—N/A

Div Yield

5.0%89.5

Momentum

52W High %

87%81.5

RS 6M

27%84.8

SMA 50/200

1.20x87.9

EPS Rev 4W

0.0%34.4

EPS Rev 12W

0.0%41.6

EPS Improve

-102%5.1

Q Growth

488%96.7

FUNDAMENTALS

Market Cap

$209M

P/E (Forward)

-62.6x

Gross Margin

0.7%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of ORMP are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
ORMP	Oramed Pharmaceuticals Inc.(you)	$209M	80	Strong Buy
AGEN	Agenus Inc.	$345M	75	Buy
PLX	Protalix BioTherapeutics, Inc.	$205M	97	Strong Buy
1521.HK	Frontage Holdings Corporation	$310M	93	Strong Buy
QTTB	Q32 Bio Inc.	$447M	87	Strong Buy
ICCC	ImmuCell Corporation	$90M	74	Buy
MDXG	MiMedx Group, Inc.	$656M	73	Buy
TBPH	Theravance Biopharma, Inc.	$885M	77	Buy
ZVRA	Zevra Therapeutics, Inc.	$687M	90	Strong Buy
PBYI	Puma Biotechnology, Inc.	$468M	98	Strong Buy

Peer medians: ROE -30.7% · P/E 27.1x · Gross margin 58.3%